Want to see SE:CEVI full AI Analyst Report?
CEVI Stock Chart & Stats
kr164.00
kr1.80(1.29%)
At close: 4:00 PM EDT
kr164.00
kr1.80(1.29%)
Day’s Range― - ―
52-Week Rangekr117.60 - kr192.20
Previous CloseN/A
Volume12.68K
Average Volume (3M)29.85K
Market Cap
kr3.96B
Enterprise Valuekr3.13B
Total Cash (Recent Filing)kr172.19M
Total Debt (Recent Filing)kr52.27M
Price to Earnings (P/E)31.1
Beta0.85
Next Earnings
Oct 29, 2026EPS Estimate
1.43Next Dividend Ex-DateN/A
Dividend Yield1.66%
Share Statistics
EPS (TTM)5.41
Shares Outstanding23,851,547
10 Day Avg. Volume31,249
30 Day Avg. Volume29,847
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.06
Revenue Forecast (FY)kr776.50M
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityCellaVision has maintained high gross and EBIT margins across several periods, indicating attractive economics in its digital diagnostics model. This profitability provides resources for continued innovation, commercial expansion, and resilience while supporting durable earnings generation.
Conservative Balance SheetVery low leverage materially reduces financial risk and preserves flexibility for research, product launches, and commercial investment. The stronger equity base also gives CellaVision greater capacity to absorb regional weakness or temporary cash-flow volatility without relying heavily on debt.
Product And Market ExpansionThe Bone Marrow application expands CellaVision’s addressable diagnostic workflow and has already generated initial customer interest in EMEA. U.S. regulatory clearance could broaden adoption and add an estimated 1–2 percentage points to growth by year-end.
Bears Say
Near-term Revenue DecelerationThe decline in trailing revenue and profitability shows that momentum has softened after a stronger 2025. If this persists, slower utilization of the installed commercial platform could limit operating leverage and make near-term earnings growth less consistent.
Volatile Free Cash FlowAlthough operating cash generation remains healthy, lower free cash flow and working-capital absorption make cash conversion less predictable. Continued volatility could reduce internally funded investment capacity and create greater variability in shareholder returns.
APAC And China WeaknessWeak APAC performance, particularly in China, is a direct regional drag on growth and demonstrates that demand is uneven across CellaVision’s geographic footprint. Prolonged weakness could offset gains in the Americas and delay broader revenue acceleration.
CellaVision AB News
CEVI FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was kr117.60 and its highest was kr192.20 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is kr3.96B.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Oct 29, 2026 which is in 9 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Jul 17, 2026. The company reported kr1.37 earnings per share for the quarter, beating the consensus estimate of kr1.339 by kr0.031.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB pays a Annually dividend of kr2.75 which represents an annual dividend yield of 1.66%. See more information on CellaVision AB dividends here
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 1.43.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of kr1.37 in its last earnings report, beating expectations of kr1.339. Following the earnings report the stock price went up 7.76%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in SE:CEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
CEVI Company Deck
CEVI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and commercial picture: solid top-line growth (4.5% YoY; ~6% organic), record Americas performance (+≈59% in Americas sales), healthy margins (70% gross margin; 27% EBITDA margin) and progress on strategic initiatives (Bone Marrow launch, FDA 510(k) process, FPM development). Offsetting risks include APAC weakness (notably China), a distributor inventory adjustment in EMEA that depressed near-term sales, increased working capital leading to a negative total cash flow for the quarter, one-time CEO transition costs (SEK 9m) and temporary operational disruptions (SEK 2m delayed reagents). On balance, the positives — strong regional recovery in the Americas, product/reagent momentum in key markets, continued R&D investment and a solid cash buffer — outweigh the transitory and region-specific headwinds.View all SE:CEVI earnings summariesTechnical Analysis
BICO Group AB Class B
―
SciBase Holding AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Acarix AB
―